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Modern medical ethics in general, and specifically in regard
to genetics, traditionally revolved around individuals and
their care providers. Common well-deliberated issues
stemming from this perspective include consent to testing
and treatment; the right to receive information and the
correlative duty of others to maintain confidentiality; or the
duty to warn family members of genetic risks. Indeed,
genetics is powerfully and widely perceived as a most
private, individually-related object—“my personal future
diary”. Therefore, lacking an individual’s consent, a
researcher may not conduct research on individual’s body
or genes. Are these autonomy-driven concepts (“respect for
person”) rightly applicable to biobanks and population
genomics?
In biobanking for population genomics, each individual’s
contribution means very little, the aggregate is essential.
Collective data, shared and relevant to participants as well
as non-participants is the new theme to be examined. Thus,
it can be argued that the traditional focus on individual
rights fails to address this new ‘public’ subject of research
and its interests.
Devising the rights of the population to be considered along
with individual’s rights must strike a desirable balance
between the goals of improving the health of the commu-
nity and protecting human dignity and human rights. This
quest, which follows the transition from genetics to
genomics, from proteins to proteomics, should transform
traditional, individually centered ethics to what I term
ethiomics. Some aspects of ethiomics will be discussed,
with a special emphasis on the need for creating means for
group engagement.
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Predictive, preventive and personalised medicine is gradually
expressing its potential to be accepted by all healthcare
institutions, healthcare professionals, politicians, as well as the
general public.
Correct and plausible predictions, active and early preven-
tion, and personalised attitude will undoubtedly bring a
higher quality of life to the patient and potentially great
economical advantages for the entire society. As the
concept evolves, it gets more and more evident that from
the social and economical point of view it is the only way
for the future sustainable healthcare. The patient’s rights,
however, should guarantee that any preventive actions
arising of the predictions are not forced upon the patient
or any individual in “pre-patient” condition. The patient’s
rights should also guarantee that the patient’s data cannot be
analysed and consequently, the prediction cannot be made,
without either prior written consent or any other form of
active approval that is manageable with the current
information technology.
If informed about the predictive diagnosis, the patient must
always be told that the particular prediction is based upon
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the latest knowledge available and that this may be refined,
or even changed, when new knowledge or data is available
and entered into the system. In this way, the patient
becomes more involved, motivated and interested in
targeted preventive actions that, in turn, may in many cases
lead to less stress, better long-term outcomes and better
quality of everyday-life even in situations which, otherwise,
will be difficult to cope with.
Legislatively and technically, the patient should be guaran-
teed permission to view his/her own medical records and to
check who else, if anyone, has access to his/her medical
records, what changes are been made, if any, who authorises
access and for what purpose, as well as another possible data
logged.
The ethical aspect of predictive, preventive and personal-
ised medicine, of course, must be supported and guaranteed
by (a) implementing relevant new legislation, which must
be clear and effective enough to eliminate any possibility of
misusing the entire concept, and by (b) a regular healthcare
education of the public and the professionals. The legisla-
tion must pay attention primarily to the health of an
individual person, keeping it at the spotlight of the
healthcare, instead of favouring public health. As a result
we can expect that the overall population statistics, the
public health, will improve. No discrimination on the basis
of prediction must be allowed under related legislation.
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Most of the ethical aspects of personalized medicine are
connected with the pharmacogenetics, genetic screening
and impact on healthcare. The pharmacogenetics raises
following ethical problems:
– the issues of ensuring equality in medical care,
– when genetics predicts patients less likely to benefit
from the available pharmacotherapy
– the right to deny an available treatment to specific
patient population depending on the information
derived from pharmacogenetic studies.
There is a number of serious questions, ranging from
consent and confidentiality of the genetic information
yielded from the tests to whether the tests should be
available over the counter or through the Internet.
There are concerns that pharmacogenetics may cause inequal-
ity in healthcare. The ability to sequence an individual’s entire
genome will enable production of high amount of detailed
genetic information, all known genetic predispositions will be
available. The ethical issues concerning the access to and use
of genetic information will arise.
The development of two technology platforms, namely
biobanks and large health records systems are shifting the
paradigm in bioethics thinking. Biobanks are important
resources in pharmacogenomics in which individual samples
may be studied to establish genotype-phenotype relationships
between genetic genetic variation, gene expresion, and disease
susceptibility or drug response. Biobanks implicate both
clinical and research ethics issues in new ways.
Despite general public support for genetic studies including
the use of stored tissues to test and designe new medicines,
there still remains distrust of efforts to commercialize the
results of the genomic research.
There will be several ethical issues for physicians who have
to be able to discuss the latest biomarker studies and their
implications for the disease management.
On the other side, personalized medicine proposes the
new paradigm to limit the rising healthcare costs. If we
will be able to make a better use of the accumulating
knowledge to chose the optimal approach tailored to an
individual, we will be able to save money of ineffective
therapies and adverse events. Personalized medicine will
bring together the efforts by pharmaceuticals, healthcare
provides, patients, insurance companies, researchers and
policy makers. Well treated ethical issues should allow
for benefits by all parties involved.
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